Urologix Announces Poster Presentation at the 2014 Annual Meeting of the American Urological Association
06 Mayo 2014 - 3:05PM
The poster "Cost-Effectiveness Markov Model Comparing
High- and Low-Energy Transurethral Microwave Therapy for Benign
Prostatic Hyperplasia" will be presented Tuesday morning,
May 20th, by Dr. Ulchaker from the Cleveland Clinic.
Urologix, Inc. (OTCQB:ULGX), the market leader for In-Office BPH
Therapy, today announced that data demonstrating the
cost-effectiveness of high energy Transurethral Microwave Therapy
(TUMT) versus low energy alternatives will be presented at the
American Urological Association (AUA) 2014 Annual Meeting to be
held May 16 – 21, 2014, at the Orange County Convention Center in
Orlando, Florida.
The poster will be presented Tuesday morning, May 20th at
10:30am ET, by James C. Ulchaker, MD, a practicing Urologist with
the Cleveland Clinic. His presentation will review results
from a clinical and economic model that calculates the
cost-effectiveness of Low Energy Transurethral Microwave Therapy
(LE-TUMT) and High Energy (HE) TUMT, such as Urologix's Cooled
ThermoTherapy. The model incorporates a review of the peer
reviewed published data on these two classes of TUMT technologies
and factors in the Medicare costs, published outcomes, side effects
and retreatment rates. The results indicate that the HE-TUMT
technologies are less expensive and more effective over time.
"The elderly population is growing, and the cost and quality of
life impacts of BPH among aging men are growing with it.
Estimates put the annual direct costs to treat BPH today at over $4
billion. There is a great need to expand our knowledge of how
decisions on technology and treatment selection for BPH affect
healthcare costs as well as outcomes. These types of clinical
and economic models are important first steps to help shine a light
on comparing cost effectiveness," stated Dr. Jim Ulchaker of the
Cleveland Clinic.
"In today's healthcare system, there is a growing mandate that
everyone involved evaluate both the costs and the effectiveness of
treatment choices," commented Greg Fluet, Chief Executive Officer
of Urologix. "We are excited to help support research that will
enable urologists, patients and payers to make more knowledgeable
decisions and understand the cost-effective treatment options for
BPH patients we offer. Their choices can potentially save
patients and the healthcare system thousands of dollars per
patient."
Urologix offers early and effective treatment options for
obstructive and symptomatic urinary conditions due to benign
prostatic hyperplasia (BPH) and provides urologists with two proven
technologies to treat the widest range of patients, with Cooled
ThermoTherapy™ and Prostiva® RF Therapy. BPH, also known as
enlarged prostate, affects the majority of men as they age and can
create irritating symptoms which significantly impact quality of
life. This disease continues to be predominantly treated with
medications; however, research has shown that drugs are not always
effective and can produce unpleasant side effects. Cooled
ThermoTherapy and Prostiva RF Therapy have proven their results
through numerous clinical studies and are recommended treatment
options within American Urology Association guidelines. To learn
more about Urologix and these products, visit www.urologix.com.
About Urologix
Urologix, Inc., based in Minneapolis, develops, manufactures,
markets and distributes minimally invasive medical products for the
treatment of obstruction and symptoms due to Benign Prostatic
Hyperplasia (BPH). Urologix's Cooled ThermoTherapy produces
targeted microwave energy combined with a unique cooling mechanism
to protect healthy tissue and enhance patient comfort. The
Prostiva RF Therapy System delivers radio frequency energy directly
into the prostate destroying prostate tissue, reducing constriction
of the urethra, and thereby relieving BPH symptoms. Both of
these therapies provide safe, effective and lasting relief of
obstruction and symptoms due to BPH. Prostiva is a registered
trademark of Medtronic, Inc., used under license. All other
trademarks are the property of Urologix.
Federal USA law restricts these devices to sale by or on the
order of a physician. For more complete information about the
benefits, risks and contraindications associated with Cooled
ThermoTherapy and Prostiva RF Therapy, please refer to the product
labeling which accompanies the device and can be found on the
Urologix website.
If you would like more information on this topic, please contact
Susan Overby at 763-745-1540 or soverby@urologix.com. To learn more
about Urologix and its products and services, visit
www.urologix.com.
The Urologix logo is available at
www.urologix.com/clinicians/resource-library.php.
CONTACT: Urologix Media Contact
Susan Overby
763-745-1540
soverby@urologix.com
Urologix Investor Relations Contact
Brian Smrdel
(763) 475-7696
bsmrdel@urologix.com
Urologix (CE) (USOTC:ULGX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Urologix (CE) (USOTC:ULGX)
Gráfica de Acción Histórica
De May 2023 a May 2024